Opportunityanalyzer: Acute Myeloid Leukemia (Aml)-Opportunity Analysis And Forecasts To 2024: Ken Research Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report.… Read More »
